Ovid Therapeutics Inc (OVID)

$1.69 +0.07 (4.01%)
Market Cap 111.09M
Revenue (ttm) 570,000.00
Net Income (ttm) -26.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,636.84%
Debt to Equity Ratio 0.00
Volume 1,152,160
Avg Vol 3,265,086
Day's Range N/A - N/A
Shares Out 71.21M
Stochastic %K 66%
Beta 0.04
Analysts Strong Sell
Price Target $4.67

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 661 7661
Fax: 646 661 4027
Address:
441 Ninth Avenue, 14th Floor, New York, United States
AAROELA
AAROELA Dec. 4 at 2:29 PM
$OVID Remember folks. Phase 1 data selected for presentation at American Epilepsy Society (AES): The OV329 Phase 1 study results will be featured in a late-breaking poster session at the 2025 AES annual meeting, occurring December 5-9, 2025 in Atlanta, Georgia.
0 · Reply
hitmongreen
hitmongreen Dec. 3 at 9:08 PM
$OVID more coming
0 · Reply
hitmongreen
hitmongreen Dec. 3 at 2:29 PM
$OVID buying heavily
0 · Reply
stockinghead
stockinghead Dec. 2 at 9:48 PM
$OVID what happened here, did I miss something
0 · Reply
lucabrix
lucabrix Dec. 2 at 4:55 PM
$OVID 1.80 is hard to pass, but we will!!
0 · Reply
hitmongreen
hitmongreen Dec. 2 at 4:50 PM
$OVID 👀
0 · Reply
BiodegradableBurger
BiodegradableBurger Dec. 2 at 4:22 PM
$OVID A week’s gain lost in half a day. Utterly absurd.
2 · Reply
Achouffe
Achouffe Nov. 30 at 10:33 AM
$OVID I must admit that my BEP is still a way to go for BE. Should I double or should I sell.
0 · Reply
michaelhearn
michaelhearn Nov. 28 at 10:22 PM
$OVID happy my order was filled on that morning dip. Doubled my position
2 · Reply
foolforlove20
foolforlove20 Nov. 28 at 5:10 PM
$OVID target of 4.72 next six months. Long target of 11.73 by eoy 2027.
0 · Reply
Latest News on OVID
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Dec 2, 2025, 7:00 AM EST - 3 days ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 23 days ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 12:52 PM EDT - 2 months ago

Ovid Therapeutics Inc. - Special Call

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:05 AM EDT - 2 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Oct 3, 2025, 7:00 AM EDT - 2 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jul 23, 2025, 8:30 AM EDT - 4 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 7 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 9 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Mar 3, 2025, 8:00 AM EST - 9 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 10 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 10 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Sep 26, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

AAROELA
AAROELA Dec. 4 at 2:29 PM
$OVID Remember folks. Phase 1 data selected for presentation at American Epilepsy Society (AES): The OV329 Phase 1 study results will be featured in a late-breaking poster session at the 2025 AES annual meeting, occurring December 5-9, 2025 in Atlanta, Georgia.
0 · Reply
hitmongreen
hitmongreen Dec. 3 at 9:08 PM
$OVID more coming
0 · Reply
hitmongreen
hitmongreen Dec. 3 at 2:29 PM
$OVID buying heavily
0 · Reply
stockinghead
stockinghead Dec. 2 at 9:48 PM
$OVID what happened here, did I miss something
0 · Reply
lucabrix
lucabrix Dec. 2 at 4:55 PM
$OVID 1.80 is hard to pass, but we will!!
0 · Reply
hitmongreen
hitmongreen Dec. 2 at 4:50 PM
$OVID 👀
0 · Reply
BiodegradableBurger
BiodegradableBurger Dec. 2 at 4:22 PM
$OVID A week’s gain lost in half a day. Utterly absurd.
2 · Reply
Achouffe
Achouffe Nov. 30 at 10:33 AM
$OVID I must admit that my BEP is still a way to go for BE. Should I double or should I sell.
0 · Reply
michaelhearn
michaelhearn Nov. 28 at 10:22 PM
$OVID happy my order was filled on that morning dip. Doubled my position
2 · Reply
foolforlove20
foolforlove20 Nov. 28 at 5:10 PM
$OVID target of 4.72 next six months. Long target of 11.73 by eoy 2027.
0 · Reply
BioStick123
BioStick123 Nov. 28 at 4:55 PM
$OVID entered $1.70. Ra Cap pipe. Trading at near $0 EV
0 · Reply
REDWIR
REDWIR Nov. 28 at 4:54 PM
$APLD $OVID 22 percent gains from both this week!
0 · Reply
lucabrix
lucabrix Nov. 28 at 4:41 PM
$OVID just on the right way!!!
0 · Reply
aletz
aletz Nov. 27 at 6:52 PM
$OVID https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ Top 5 from this week's AI scanner
0 · Reply
lucabrix
lucabrix Nov. 26 at 8:24 PM
$OVID TP 7$!!
0 · Reply
littlestash
littlestash Nov. 26 at 7:25 PM
$OVID taking off 💸
0 · Reply
littlestash
littlestash Nov. 26 at 3:03 PM
$OVID looking like a good setup here 💸
0 · Reply
don_111
don_111 Nov. 26 at 2:46 PM
$OVID Starting to recover.
0 · Reply
masonat
masonat Nov. 24 at 7:43 PM
$OVID OV329 probably makes this worth an investment all by itself. KCC2 pipeline just a bonus if it happens to work.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Nov. 24 at 2:59 PM
$CGEM $NXTC $NKTR $OVID Monday is on fire!!
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 2:56 PM
HC Wainwright & Co. updates rating for Ovid Therapeutics ( $OVID ) to Buy, target set at 1.5 → 2.
0 · Reply
REDWIR
REDWIR Nov. 24 at 2:11 PM
$RZLV $APLD $OVID PRIMED FOR GAINS THIS WEEK
0 · Reply